Last reviewed · How we verify
Von Hippel-Lindau (VHL) disease
Approved treatments
- Welireg · Merck & Co.
Belzutifan inhibits HIF-2α, blocking its interaction with HIF-1β to reduce expression of genes linked to tumor growth.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Von Hippel-Lindau (VHL) disease patent landscape — cliff calendar, originator estates, attackable patents
- Von Hippel-Lindau (VHL) disease treatment landscape brief
- Von Hippel-Lindau (VHL) disease treatment updates RSS
Frequently asked questions about Von Hippel-Lindau (VHL) disease
What drugs treat Von Hippel-Lindau (VHL) disease?
Tracked treatments include Welireg.
What is the treatment for Von Hippel-Lindau (VHL) disease?
Standard treatment for Von Hippel-Lindau (VHL) disease includes Welireg. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Von Hippel-Lindau (VHL) disease patent cliff · Von Hippel-Lindau (VHL) disease CI report
- Treatment: Welireg · Merck & Co.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing